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ABSTRACT
We have shown that some patients presenting with
chronic bronchodilator-resistant non-productive cough
have global atopic tendency, airway cough hyper-
sensitivity without non-specific bronchial hyperrespon-
siveness and eosinophilic inflammation of the trachea
and bronchi, abbreviated as atopic cough (AC).
Histamine H1 receptor antagonists are effective in
relieving the cough in some patients with AC but not in
others in whom corticosteroids are needed to improve
the cough. The aim of the present study was to
compare the intensity of eosinophil infiltration in biop-
sied bronchial submucosa and sequential broncho-
alveolar lavage (SBAL) fluids between two subgroups
of patients with AC: (i) group A, successfully treated
with histamine H1 receptor antagonists; and (ii) group
B, requiring corticosteroids. Sequential BAL was per-
formed using three 50 mL aliquots of physiologic
saline solution and then bronchoscopic bronchial
biopsy was performed in group A (n = 9) and B (n = 9)
patients. Sequential BAL was also performed in normal
controls (NC; n = 13). The first SBAL fraction was
analyzed as bronchial lavage fluid (BLF) and the mixed
fluid of the second and third SBAL fractions as
bronchoalveolar lavage fluid (BALF). The number of
eosinophils in the bronchial subepithelium was signifi-
cantly (P = 0.0134) greater in group B patients
(median 8.3 cells/mm2; range 3.6–21.9 cells/mm2)
compared with group A (median 3.6 cells/mm2; range
0–10.0 cells/mm2). However, There were no signifi-
cant differences in the number or percentage of
eosinophils in BLF or BALF between group A, group B
and NC subjects. These findings confirm that eosino-
phils do not infiltrate the peripheral airways of AC and
suggest that corticosteroids are required to relieve the
cough in more severe illness of AC, in which sub-
mucosal eosinophilic inflammation of the central
bronchi is more intensive compared with the milder
illness successfully treated with histamine H1 receptor
antagonists.
Key words: atopic cough, atopy, bronchial biopsy,
bronchial lavage, bronchoalveolar lavage, chronic
non-productive cough, eosinophils, sequential broncho-
alveolar lavage.
INTRODUCTION
Cough is a common presenting symptom in both general
practice and in the chest clinic. Patients presenting with
chronic non-productive cough resistant to antibiotics and
the usual antitussive agents are frequently referred to our
clinic for diagnosis and treatment. Post-nasal drip-
induced cough, gastroesophageal reflux (GER)-associated
cough and cough variant asthma (CVA) are well-known
causes of non-productive cough.1 Cough variant asthma
is characterized by mild bronchial hyperresponsiveness
and a good response to bronchodilators, such as 
b 2-adrenoceptor agonists and theophylline.2,3 Sensitivity
of the cough response to inhaled capsaicin is not height-
ened in either CVA4,5 or classical asthma.6
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We have proposed a bronchodilator-resistant non-
productive cough associated with global atopic basis
(abbreviated as atopic cough; AC) as a new clinical
entity,7 which is successfully treated with selective hista-
mine H1 receptor antagonists and/or glucocortico-
steroids.4,5,7,8 In such patients, non-specific bronchial
responsiveness is within normal limits4,5,7,8 and airway
cough sensitivity to inhaled capsaicin is heightened.4,5,7
Eosinophils are frequently detected in hypertonic saline-
induced sputum5 and biopsied submucosa of the trachea
and bronchi, but not in bronchoalveolar lavage fluid
(BALF).7 Thus, eosinophilic tracheobronchitis with airway
cough hypersensitivity is the fundamental feature of AC.7
Histamine H1 receptor antagonists are effective in
nearly 60% of patients with AC, and oral (prednisolone
20 mg/day for 14 days or less) and/or inhaled cortico-
steroids (beclomethasone dipropionate, 400–800 m g/day)
successfully improve the cough that is resistant to hista-
mine H1 receptor antagonists within 14 days in the
majority of patients.4,5,7,8 The present prospective study
was conducted to elucidate whether the intensity of
bronchial eosinophilic inflammation contributes to the
requirement of corticosteroids and to ensure no BAL
eosinophilia in AC that we previously reported,7 using the
sequential bronchoalveolar lavage (SBAL) technique.
METHODS
Patients
The present study was approved by the local ethics com-
mittee of Ishikawa Prefectural Central Hospital. Of 86
consequent patients who were referred to our pulmonary
subspecialty clinic for further examination of their chronic
non-productive cough between April 1991 and March
1992, 18 immunocompetent patients participated in 
the study and underwent bronchoscopic examinations
including bronchial biopsy and SBAL. All patients gave
their informed consent after the purpose of the study had
been explained. Each patient met the following diagnostic
criteria of AC: (i) chronic non-productive cough with a
‘tickle’ in the throat lasting for more than 8 weeks that was
resistant to bronchodilator therapy (oral clenbuterol, 
40 m g/day, and inhaled procaterol on demand for at least
1 week); (ii) the absence of wheeze, dyspnea, hemoptysis
or pleurisy and no adventitious lung sounds on examina-
tion; (iii) non-specific bronchial responsiveness to metha-
choline within normal limits; (iv) the presence of one or
more of the following atopic findings as a global feature: 
a past history and/or complications of allergic diseases
except for bronchial asthma, a family history of allergic dis-
eases, peripheral blood eosinophilia, elevated total IgE
levels in serum, positive specific IgE antibody to common
aeroallergens and positive allergen skin test; (v) normal
forced expiratory volume in 1 s (FEV1), forced vital capacity
(FVC) and FEV1/FVC ratio; (vi) no bronchial reversibility
defined as a less than 10% increase in FEV1 after inhalation
of 300 m g salbutamol; (vii) complete relief of cough fol-
lowing treatment with histamine H1 receptor antagonists
(terfenadine, ketotifen and/or azelastine) and/or glucocor-
ticoid therapy (inhaled beclomethasone dipropionate
and/or short-term oral prednisolone); and (viii) the
absence of well-known causes of cough such as GER,
post-nasal drip and chronic bronchitis.
Bronchial responsiveness was measured using metha-
choline according to the method described by Takishima
et al.9 (Astograph TCK-6000 CV; Chest Co. Ltd, Nagoya,
Japan). Results are expressed as the provocative concen-
tration of methacholine required to cause a 35%
decrease from the baseline respiratory conductance
(PC35-Grs, mg/mL).
Peripheral blood eosinophils were counted using a
Microx Cell Analyzer HEG-120 (Omron, Kyoto, Japan)
on the day before bronchoscopy. Total serum IgE levels
were determined using the Phadebas paper radio-
immunosorbent test (Pharmacia Diagnostics, Uppsala,
Sweden). Serum-specific IgE antibodies were also 
measured by the Phadebas radioallergosorbent test
(Pharmacia Diagnostics). All patients had normal sinus
and chest radiographs.
Thirteen normal non-smokers without respiratory symp-
toms (seven men and six women; median age 58 years;
range 17–70 years) underwent SBAL as a control group.
Sequential bronchoalveolar lavage and
bronchial biopsy
Before treatment, flexible fiberoptic bronchoscopy
(Olympus BF 1T-20; Olympus, Tokyo, Japan) was per-
formed under local anesthesia with lidocaine following
premedication with atropine sulfate and hydroxyzine.
Sequential BAL was performed in the right middle lobe
using three 50 mL aliquots of physiologic saline solution.
The first lavaged fraction and the mixed fluid of the
second and the third lavaged fractions were separately
analyzed as bronchial lavage fluid (BLF) and BALF,
respectively. A part of the recovered BALF was used for
bacteriological and cytological examinations. After parts
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of the BLF and the BALF were diluted with an equal
volume of Türk solution, cells were counted in a Bürker
chamber (Nichirim Co. Ltd, Tokyo, Japan). After the
remaining BLF and BALF were passed through a double
layer of Dacron net, cells were pelleted at 300 g for 10
min and resuspended in 10 mL RPMI-1640 (Grand
Island Biological Co., Grand Island, NY, USA). The fluids
were resuspended to a concentration of 2 · 105 cells/mL.
Smears for differential counts were prepared by cytocen-
trifugation (Cytopin 2; Shadon Southern Instruments,
Sewickleyo, USA) at 70 g for 10 min. After staining with
May–Grünwald–Giemsa, a differential cell count was
done in 300 cells.
Histologic examination was performed with special
emphasis on eosinophils. Airway mucosa specimens were
obtained by bronchoscopic forceps biopsy at a bifurcation
of the right upper lobe bronchus and truncus intermedicus
and/or at the opening of the right middle lobe as
bronchial mucosa (total of two or three specimens).
Biopsied specimens were fixed in formalin solution,
embedded in paraffin and cut through its entire thickness
at 4 m m, all sections being mounted and stained with
hematoxylin and eosin. Light microscopic examination
was performed independently by two pathologists, who
were not aware of the clinical findings, in order to identify
the number of eosinophils. Numbers of eosinophils in
subepithelium were counted using an eyepiece graticule
and the counted eosinophil numbers of two or three spec-
imens were then averaged. Results are expressed as the
average of the eosinophil numbers counted by the two
pathologists (cells per 1 mm2 area of subepithelium).
Treatment protocol
After bronchoscopic examinations, each patient was given
a 7 day oral course of histamine H1 receptor antagonists
(ketotifen 2 mg/day, azelastine 4 mg/day or terfenadine
120 mg/day). If the cough did not fully resolve on treat-
ment, glucocorticoid therapy (prednisolone 0.5 mg/kg/day
for 7–14 days) was added.
Statistical analysis
Data are shown as the median (range). Statistical differ-
ences were determined by Mann–Whitney U-test between
any pairs of groups. Spearman’s regression analysis was
used in assessing correlations between the degree of
eosinophil infiltration in biopsied bronchi and eosinophil
counts in BLF, BALF and peripheral blood. Significance
was based on a 95% confidence level (P< 0.05).
RESULTS
The cough was completely relieved by oral histamine H1
receptor antagonists in nine of 18 patients (patients 1–9;
group A). In the remaining nine patients (patients 10–18;
group B) the cough was not fully relieved following hista-
mine H1 receptor antagonist treatment but was completely
resolved following oral glucocorticoid therapy within
7–14 days (Table 1).
Intraepithelial eosinophil infiltration was not investigated
in any patient. Eosinophils were detected in the subepithe-
lial lamina propria in seven patients in group A and nine
patients in group B (Fig. 1). The degree of eosinophil infil-
tration observed in the biopsied bronchi was significantly
(P = 0.0134) stronger in patients in group B (median 
8.3 cells/mm2, range 3.6–21.9 cells/mm2) than group A
(median 3.6 cells/mm2, range 0–10.0 cells/mm2).
Bronchial lavage fluid was successfully recovered from
nine and seven patients in groups A and B, respectively.
Total cell counts in BLF were 0.6 (0.3–3.5), 1.1 (0.2–2.8)
and 0.6 (0.04–3.4) · 105 cells/mL in group A, group B
and the control group, respectively, and there were no
significant differences between any pairs of the groups.
Although an increase of percentage eosinophils in BLF
(5% or more) was investigated in one patient each 
of group A and group B (Fig. 2), the percentage of
eosinophils in BLF was not significantly different among
group A, group B and the control group. The absolute
number of eosinophils in BLF was 0.0 (0.0–0.36), 0.01
(0.0–2.38) and 0.0 (0.0–0.34) · 104 cells/mL in group
A, group B and the control group, respectively, and the
values were not significantly different.
Bronchoalveolar lavage fluid was obtained from all
patients. The total cell count was 1.2 (0.8–3.1), 1.8
(1.0–4.4) and 1.5 (0.3–3.8) · 105 cells/mL in group A,
group B and the control group, respectively, and these
values were not significantly different. There was no
increase of eosinophils in BALF, whereas lymphocytes
were increased to 20% or more in two and three patients
of groups A and B, respectively (Fig. 3). The number of
eosinophils or lymphocytes was not significantly different
among group A, group B and the control group.
Two patients (patients 1 and 14) had an increase in
total cells and neutrophils in BLF and further examination
revealed that they were complicated with very mild sino-
bronchial syndrome. When the biopsy, BLF and BALF
data were re-analyzed excluding the two patients, the sig-
nificant difference between group A and group B was
observed only in bronchial submucosal eosinophils.
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Peripheral blood eosinophil counts, serum IgE level,
pulmonary function, or PC35-Grs were not significantly
different between group A and group B (Table 1).
The degree of eosinophil infiltration in the subepithe-
lium was not significantly correlated with the percentage
or the number of eosinophils in BLF or BALF, the number
of peripheral blood eosinophils, serum IgE levels or 
PC35-Grs in patients with chronic cough (group A plus
group B; Table 2).
DISCUSSION
Chronic persistent non-productive cough is pathologic to
be troublesome itself, whereas productive cough is physio-
logic to expectorate abnormal secretions and foreign
bodies from the lower respiratory tract. Our working
hypothesis is that the pathologic cough occurs because
of at least the following two mechanisms: (i) broncho-
constriction based on mild bronchial hyperresponsiveness
in CVA;2,3 and (ii) cough receptor hypersensitivity in
AC,4,5 cough induced by angiotensin-converting enzyme
inhibitors,10 GER-associated cough11 and idiopathic dry,
unproductive cough.10 Hyperstimulation has been postu-
lated as another mechanism of coughing in post-nasal
drip-induced cough.12 Sensitivity of the cough reflex is
independent of bronchial responsiveness6 and broncho-
motor tone.13 Recently, AC has been recognized as a new
clinical entity presenting with chronic non-productive
cough resistant to bronchodilator therapy.7 Eosinophilic
tracheobronchitis and airway cough hypersensitivity are
histologic and pathophysiologic features of AC, respect-
ively.7 We have experienced more patients whose illness
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Fig. 1 Number of eosinophils in bronchial submucosa was
determined from transbronchoscopic biopsies from patients
with chronic bronchodilator-resistant non-productive cough
associated with an atopic basis (atopic cough). Group A,
patients whose cough was relieved by histamine H1-antagonists
(n = 9); group B, patients whose cough was relieved by gluco-
corticoids, but not by histamine H1-antagonists (n = 9). Each
horizontal bar represents the median. Difference was deter-
mined by Mann–Whitney U-test.
Fig. 2 Individual data on cell dif-
ferentials in bronchial lavage fluid
(BLF) recovered from patients with
chronic bronchodilator-resistant
non-productive cough associated
with an atopic basis (atopic
cough). The BLF refers to the first
fraction of sequential broncho-
alveolar lavage. A, patients whose
cough was relieved by histamine
H1-antagonists (n = 9); B, patients
whose cough was relieved by
glucocorticoids, but not by hista-
mine H1-antagonists (n = 7); NC,
normal controls.
was diagnosed as AC in comparison with those with CVA.
Previous data14 have shown that AC, CVA and others
were, respectively, diagnosed in 34 (56.6%), 24 (40.0%)
and two (3.4%) of 60 consequent patients presenting with
chronic non-productive cough only who were referred to
our chest and allergic clinic between 1 June 1990 and
31 January 1992.
The present study, with special emphasis on eosin-
ophils, showed that eosinophils infiltrated in the sub-
epithelium, but not the epithelium, of biopsied bronchi,
while eosinophils in BLF or BALF were not increased in
patients with AC. In addition, the intensity of eosinophil
infiltration in the bronchial submucosa was not correlated
with the absolute number or percentage of eosinophils in
BLF or BALF. Eosinophils in BLF were increased above 
5% or more in only two of 16 patients in whom BLF was
successfully recovered. The two patients seem to be con-
sistent with eosinophilic bronchitis without asthma (EB),
as described later. When the patients were excluded for
data analysis, the results regarding bronchial submu-
cosal, BLF and BALF eosinophils remained unchanged.
These findings confirm our previous results that eosin-
ophils are detected in subepithelium of trachea and/or
bronchi, but not in BALF, from patients with AC.7 It is well
known that eosinophilic inflammation is present through-
out large bronchi to peripheral airways in CVA,15 as well
as in classical asthma.16 Thus, the pathological feature of
AC is different to those of CVA and asthma.
We assigned studied patients with AC to one of two
subgroups based on the successful treatment: (i) hista-
mine H1 receptor antagonists were sufficiently effective in
group A (n = 9, 50%); and (ii) oral glucocorticoid
therapy was required to relieve the cough in group B 
(n = 9, 50%). Namely, patients in group B are thought to
have a more severe illness. This result is in agreement
with that of previous reports4,5,8 that the cough is success-
fully treated with histamine H1 receptor antagonists in
nearly 60% of patients and oral and/or inhaled gluco-
corticoids successfully improve cough that is not fully
relieved by histamine H1 receptor antagonists. The
present study showed that bronchial eosinophilic inflam-
mation was more severe in patients in group B rather than
in group A, suggesting that histamine H1 receptor antag-
onists are sufficiently effective for the milder illness and
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Fig. 3 Individual data on cell differ-
entials in bronchoalveolar lavage fluid
(BALF) recovered from patients with
chronic bronchodilator-resistant non-
productive cough associated with an
atopic basis (atopic cough). The BALF
refers to mixed fluid of the second and
third fractions of sequential broncho-
alveolar lavage. A, patients whose
cough was relieved by histamine H1-
antagonists (n = 9); B, patients whose
cough was relieved by glucocorticoids,
but not by histamine H1-antagonists
(n = 9); NC, normal controls.
Table 2 Correlation of degree of eosinophil infiltration in
bronchial subepithelium to eosinophil counts in bronchial lavage
fluid, bronchoalveolar lavage fluid and peripheral blood and
serum total IgE levels in patients with chronic bronchodilator-
resistant non-productive cough with an atopic basis
P P
Bronchial lavage fluid
% 0.389 0.1324
105 cells/mL 0.421 0.1033
Bronchoalveolar lavage fluid
% 0.090 0.7116
105 cells/mL 0.014 0.9548
Peripheral blood (%) 0.041 0.8644
Total IgE (IU/mL) 0.191 0.4305
that glucocorticoid therapy is necessary for the more
severe cases.
Boulet et al.17 have shown that BALF contains an
increased number of inflammatory cells and bronchial
biopsy presents an increased epithelial desquamation
and inflammatory cells, particularly mononuclear cells, in
19 patients with chronic cough for which post-nasal drip
and GER were the etiology. In those patients, no increase
in eosinophils was found in BALF or biopsied bronchi. We
did not perform bronchial biopsy in normal subjects and
did not make a quantitative analysis on mucosal lympho-
cyte infiltration in the present study. Although the
presence of lymphocyte infiltration in biopsied bronchi
was qualitatively observed in most patients with AC, there
was no significant increase in lymphocytes in BALF, while
20% or more lymphocytes were seen in BLF or BALF in six
of 18 patients. These findings suggest that the histologic
feature of AC is different from that of post-nasal drip-
induced cough and GER-associated cough with regard to
airway eosinophil infiltration.
Recently, Gibson et al.18 showed that eosinophils and
gene expression of interleukin (IL)-5 and granulocyte–
macrophage colony stimulating factor were increased in
BALF from patients with EB and these findings did not
differ from those of asthmatic patients. Moreover, the
cough is productive in EB18,19 and non-productive in AC.
Accordingly, AC is thought to be different from EB in the
view of character of cough and BALF eosinophilia: non-
productive cough compared with productive cough and
absence compared with presence of BALF eosinophilia.
Recently, however, it has been reported that EB is diag-
nosed in 10–15% of patients with isolated chronic cough
referred to a respiratory specialist20,21 and that non-
productive cough is a sole manifestation in a part of
patients with EB20 (P Gibson, pers. comm., 1999).
Furthermore, a case of EB developing irreversible airflow
obstruction was reported.22 Effects of histamine H1 recep-
tor antagonists in EB or long-term prognosis of AC or EB
are unclear. Further studies are needed to clarify whether
AC and eosinophilic bronchitis without asthma are differ-
ent or not.
Two patients included in the present study had an
increase in neutrophils in BLF. Further examination after
complete relief of their non-productive cough revealed
that they were complicated with very mild sinobronchial
syndrome.23 Sinobronchial syndrome is a very common
chronic upper and lower respiratory tract inflammatory
disorder presenting with chronic expectoration in
Japan.24 After their severe non-productive cough had
completely resolved following treatment with ketotifen or
glucocorticoids, we found that they had a small amount
of sputum expectoration and throat clearing. As these
symptoms were not troublesome, they required no addi-
tional treatment.
The prevalence of allergen-specific IgE was low in
comparison with the high prevalence of eosinophils 
in bronchial submucosa in the present study. In our exper-
ience, house dust mite or Japanese cedar antigen are
unlikely causative agents for AC because the onset of
coughing does not coincide with the season. Recently, we
have experienced patients with AC in whom uncommon
environmental fungal antigens are causative based on an
environmental survey and antigen challenging.25–27 Thus,
routine work-up for specific IgE may be merely useful for
the evaluation of global atopic tendency, but not
causative antigens, in seeing patients with AC.
Although AC is the most common cause of chronic
non-productive cough in our district, as mentioned
above, and has been recognized in other regions of
Japan, it is unknown whether this clinical entity is relevant
in other countries. It has been reported that GER is a
common cause of chronic cough in Caucasians (5–20%
of chronic cough),1,28 but it is very rare in Japan (less than
1%),29 suggesting the possibility of racial or regional dif-
ferences in the causes of pathologic cough. Further
studies are required to establish AC in Japan in compari-
son with EB and to elucidate the possibility of differences
in causative disorders presenting with chronic cough
between countries.
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